Antipsychotics & Dementia: Managing Medications

Dr Sharon Cohen joins touchNEUROLOGY to discuss the challenges in diagnosing Alzheimer’s disease (AD) at an early stage, the most exciting recent developments in diagnostic criteria, genetic testing, and neuroimaging techniques. Dr Cohen also talks through the recent developments in biomarker strategies for diagnosis and precision management of early AD. The presentation entitled: ‘Accelerating Progress […]

Aducanumab is a human monoclonal antibody targeting soluble and insoluble amyloid beta (Aβ) aggregates. Aducanumab was approved in June 2021 for the treatment of mild cognitive impairment due to Alzheimer’s disease or mild dementia due to Alzheimer’s disease by the FDA under the accelerated approval pathway. Dr Sharon Cohen (Toronto Memory Program, Toronto, Canada) discusses […]

Dr Tim Bartels (UK Dementia Research Institute, University College London, London, UK) joins touchNEUROLOGY to discuss the highlights from this year’s AD/PD 2022 conference. He discusses some of his personal highlights in the field of new therapeutics for neurodegeneration, and also the presentation of functioning MRI agents for α-Synuclein. Question: What are some of the […]